# To Compare the Efficacy and Safey of Vildagliptin Compared to Voglibose in Patients With Type 2 Diabetes

> **NCT00368134** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 370 (—)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Vildagliptin

## Key facts

- **NCT ID:** NCT00368134
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 370 (—)
- **Last updated:** 2007-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00368134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00368134, "To Compare the Efficacy and Safey of Vildagliptin Compared to Voglibose in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00368134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*